Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L C Hartmann

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Cancer|June 15, 1995
c-erbB-2 and p53 expression in fallopian tube carcinomaM Q Lacy, L C Hartmann, G L Keeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1996
Chromosome-specific aneusomy in carcinoma of the breastD L Persons, R A Robinson, P H Hsu, et al.
The American Journal of Pathology|March 1, 1993
Interphase molecular cytogenetic analysis of epithelial ovarian carcinomasD L Persons, L C Hartmann, J F Herath, et al.
Neoplasia (New York, N.Y.)|August 10, 2000
Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer developmentM S Rogers, M A Foley, T B Crotty, et al.
Annals of Epidemiology|February 5, 2000
The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991C M Beard, L C Hartmann, E J Atkinson, et al.
Gynecologic Oncology|August 1, 1994
Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinomaL D Erickson, L C Hartmann, J Q Su, et al.
Gynecologic Oncology|November 1, 1992
Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survivalL C Hartmann, T J Sebo, N A Kamel, et al.
Cancer|November 15, 1992
Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatinJ H Edmonson, L C Hartmann, H J Long, et al.
Cancer Research|May 19, 2001
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancerV Shridhar, K C Bible, J Staub, et al.
Cancer Research|May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamineW J Urba, L C Hartmann, D L Longo, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Cancer|June 15, 1995
c-erbB-2 and p53 expression in fallopian tube carcinomaM Q Lacy, L C Hartmann, G L Keeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1996
Chromosome-specific aneusomy in carcinoma of the breastD L Persons, R A Robinson, P H Hsu, et al.
The American Journal of Pathology|March 1, 1993
Interphase molecular cytogenetic analysis of epithelial ovarian carcinomasD L Persons, L C Hartmann, J F Herath, et al.
Neoplasia (New York, N.Y.)|August 10, 2000
Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer developmentM S Rogers, M A Foley, T B Crotty, et al.
Annals of Epidemiology|February 5, 2000
The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991C M Beard, L C Hartmann, E J Atkinson, et al.
Gynecologic Oncology|August 1, 1994
Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinomaL D Erickson, L C Hartmann, J Q Su, et al.
Gynecologic Oncology|November 1, 1992
Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survivalL C Hartmann, T J Sebo, N A Kamel, et al.
Cancer|November 15, 1992
Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatinJ H Edmonson, L C Hartmann, H J Long, et al.
Cancer Research|May 19, 2001
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancerV Shridhar, K C Bible, J Staub, et al.
Cancer Research|May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamineW J Urba, L C Hartmann, D L Longo, et al.
Pageof 7